2022-RA-1032-ESGO Evaluation of intraoperative HPV test as an early marker of residual disease after HSIL surgical treatment. a prospective multicenter study. Preliminary results. (20th October 2022)
- Record Type:
- Journal Article
- Title:
- 2022-RA-1032-ESGO Evaluation of intraoperative HPV test as an early marker of residual disease after HSIL surgical treatment. a prospective multicenter study. Preliminary results. (20th October 2022)
- Main Title:
- 2022-RA-1032-ESGO Evaluation of intraoperative HPV test as an early marker of residual disease after HSIL surgical treatment. a prospective multicenter study. Preliminary results
- Authors:
- Bradbury, Melissa
Acosta, Ursula
Quesada, Alfonso
Lopez-Fernandez, Jose A
Quilez, Jose
Centeno, Cristina
Gil, Antonio - Abstract:
- Abstract : Introduction/Background: Objective: To evaluate if the intraoperative human papillomavirus (IOP-HPV) test has the same prognostic value as the HPV test performed 6 months after treatment of high-grade squamous intraepithelial Lesion (HSIL) to predict treatment failure. Methodology: Design: Prospective multicenter cohort studySetting: 22 Referral Hospitals in Spain.Population: 1824 women treated for cervical HSIL by Loop Electrosurgical Excision between May 2020 and December 2021 After LEEP an HPV test was performed immediately after excision using a Cobas (83%) or other genotyping test. Subsequently, pacients were followed with citology and HPV test, 6, 12 and 24 months after treatment. The IOP-HPV test was compared with HPV test 6 months after procedure and with surgical margins in order to detect residual disease. Results: We described results of the first 992 cases with the 6 month co-test performed. IOP HPV test was feasible (valid result 98, 5%). IOP-HPV was positive in 40%, while only 25% at 6 month test. We observed association between the IOP and 6 month HPV test (ChiSquare p= 0.0001), IOP HPV positivity and abnormal citology at 6 months (p=0.063), and positive IOP HPV test and positive surgical margins.(p=0.0001) Conclusion: Preliminary results show that IOP HPV test could be a satisfactory prognostic factor of cervical HSIL treatment result.
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 2
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 2
- Issue Display:
- Volume 32, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 2
- Issue Sort Value:
- 2022-0032-0002-0000
- Page Start:
- A379
- Page End:
- A379
- Publication Date:
- 2022-10-20
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-ESGO.813 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24561.xml